Conv. Plasma
Nigella Sativa

All azvudine studies
Meta analysis
study COVID-19 treatment researchAzvudineAzvudine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 54% Improvement Relative Risk Ventilation 0% ICU admission -100% Oxygen therapy 38% Progression 48% primary Azvudine for COVID-19  Sun et al.  LATE TREATMENT Is late treatment with azvudine beneficial for COVID-19? Retrospective 490 patients in China (December 2022 - January 2023) Lower progression with azvudine (p=0.018) Sun et al., eClinicalMedicine, May 2023 Favors azvudine Favors control

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study

Sun et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.101981
May 2023  
  Source   PDF   All   Meta
Azvudine for COVID-19
39th treatment shown to reduce risk in May 2023
*, now known with p = 0.000076 from 13 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
PSM retrospective 490 hospitalized COVID-19 patients with pre-existing conditions in China showing that azvudine was associated with a significantly lower risk of the composite outcome of disease progression, driven largely by lower rates of non-invasive respiratory support. However, there was no significant difference in all-cause mortality or other individual outcomes like ICU admission or invasive mechanical ventilation between the azvudine and control groups.
risk of death, 54.1% lower, HR 0.46, p = 0.16, treatment 5 of 245 (2.0%), control 9 of 245 (3.7%), NNT 61, odds ratio converted to relative risk, Cox proportional hazards.
risk of mechanical ventilation, no change, RR 1.00, p = 1.00, treatment 2 of 245 (0.8%), control 2 of 245 (0.8%).
risk of ICU admission, 100% higher, RR 2.00, p = 1.00, treatment 2 of 245 (0.8%), control 1 of 245 (0.4%).
risk of oxygen therapy, 38.5% lower, RR 0.62, p = 0.15, treatment 16 of 245 (6.5%), control 26 of 245 (10.6%), NNT 25.
risk of progression, 47.6% lower, HR 0.52, p = 0.02, treatment 17 of 245 (6.9%), control 31 of 245 (12.7%), NNT 18, odds ratio converted to relative risk, non-invasive respiratory support, endotracheal intubation, ICU admission, and all-cause death, Cox proportional hazards, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Sun et al., 5 May 2023, retrospective, China, peer-reviewed, 7 authors, study period 5 December, 2022 - 31 January, 2023. Contact:,,
This PaperAzvudineAll
Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
Yuming Sun, Liping Jin, Yating Dian, Minxue Shen, Furong Zeng, Xiang Chen, Guangtong Deng
eClinicalMedicine, doi:10.1016/j.eclinm.2023.101981
Background As the COVID-19 pandemic continues to spread, the number of associated deaths continues to increase, especially among those with pre-existing conditions. Azvudine is recommended as a priority treatment for patients with COVID-19, but its efficacy in patients with pre-existing conditions is unknown. Methods This is a single-centre, retrospective cohort study between December 5, 2022 and January 31, 2023 in Xiangya Hospital of Central South University in China to evaluate the clinical efficacy of Azvudine in hospitalised patients with COVID-19 and pre-existing conditions. Patients with Azvudine and controls were propensity score-matched (1:1) for age, gender, vaccination status, time from symptom onset to treatment exposure, severity at admission, concomitant treatments initiated at admission. The primary outcome was a composite outcome of disease progression, and the secondary outcome was each of these individual disease progression outcomes. The univariate Cox regression model was used to estimate a hazard ratio (HR) with 95% confidence interval (CI) for each result between the groups. Findings We identified 2118 hospitalised patients with COVID-19 during the study period, with a follow-up of up to 38 days. After exclusions and propensity score matching, we included 245 Azvudine recipients and 245 matched controls. Azvudine recipients had lower crude incidence rate of composite disease progression outcome compared with matched controls (7.125/1000 person-days vs. 16.004/1000 person-days, P = 0.018). There was no significant difference in all-cause death between these two groups (1.934/1000 person-days vs. 4.128/1000 person-days, P = 0.159). Azvudine treatment was associated with significantly lower risks of composite disease progression outcome compared with matched controls (HR: 0.49; 95% CI: 0.27-0.89, P = 0.016). A significant difference in all-cause death was not found (HR: 0.45; 95% CI: 0.15-1.36, P = 0.148). Interpretation These findings indicate that Azvudine therapy showed substantial clinical benefits in hospitalised patients with COVID-19 and pre-existing conditions, and should be considered for this population of patients.
Declaration of interests The authors declare no conflicts of interest that pertain to this work. Appendix A. Supplementary data Supplementary data related to this article can be found at https://doi. org/10.1016/j.eclinm.2023.101981.
Austin, Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations, Biom J
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients, N Engl J Med
Brown, Lang, Zhou, Why molnupiravir fails in hospitalized patients, mBio
Chen, Expert consensus on the application of Azovudine tablets in the treatment of novel coronavirus infection, Chi J China Pharm
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19, N Engl J Med
Lieber, Cox, Sourimant, SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model, Nat Commun
Liu, Pan, Zhang, Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study, Lancet Reg Health West Pac
Makady, De Boer, Hillege, Klungel, Goettsch, What is real-world data? A review of definitions based on literature and stakeholder interviews, Value Health
Pawlowski, Venkatakrishnan, Ramudu, Pre-existing conditions are associated with COVID-19 patients' hospitalization, despite confirmed clearance of SARS-CoV-2 virus, eClinicalMedicine
Ren, Luo, Yu, A randomized, open-label, controlled clinical trial of Azvudine tablets in the treatment of mild and common COVID-19, a pilot study, Adv Sci (Weinh)
Renoux, Azoulay, Suissa, Biases in evaluating the safety and effectiveness of drugs for the treatment of COVID-19: designing real-world evidence studies, Am J Epidemiol
Shen, Xiao, Sun, Real-world effectiveness of Azvudine in hospitalized patients with COVID-19: a retrospective cohort study, medRxiv, doi:10.1101/2023.01.23.23284899
Treskova-Schwarzbach, Haas, Reda, Pre-existing health conditions and severe COVID-19 outcomes: an umbrella review approach and meta-analysis of global evidence, BMC Med
Vogelberg, Klimek, Bruggenjurgen, Jutel, Real-world evidence for the long-term effect of allergen immunotherapy: current status on database-derived European studies, Allergy
Wong, Au, Lau, Lau, Cowling et al., Real-world effectiveness of early molnupiravir or nirmatrelvirritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study, Lancet Infect Dis
Wong, Au, Lau, Lau, Cowling et al., Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study, Lancet
Yu, Chang, The first Chinese oral anti-COVID-19 drug Azvudine launched, Innovation (Camb)
Zhang, Li, Wang, Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients, Signal Transduct Target Ther
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop